ProKidney Corp.
Abigail Romaine has extensive experience in strategic sourcing and procurement. Abigail currently holds the position of Director of Strategic Sourcing at ProKidney Corp. Before that, they worked at CRISPR Therapeutics as an Associate Director and later as a Senior Manager of Strategic Sourcing. At CRISPR, they led and managed the category strategy for analytical testing and supported analytical tech transfers. Abigail also established the strategic sourcing team for a new internal manufacturing plant and onboarded over 100 suppliers and service providers.
Prior to their time at CRISPR Therapeutics, Abigail held the role of Senior Manager of Cell Therapy Strategic Sourcing at Bristol-Myers Squibb and Senior Sourcing Manager at Celgene. Abigail gained experience in commercialization and scaling up activities of cell and gene therapy products while working as a Sourcing Manager at Novartis. In this role, they developed and maintained the category strategy, led sourcing projects, and participated in contract negotiations.
Abigail's earlier experience includes working at Novartis as a Program Specialist, where they managed requisitions, budgets, and vendor relationships. Abigail also worked as a Veterinary Technician at Novartis, where they performed daily treatments and maintained electronic records.
Before joining Novartis, Abigail worked at the USDA as an Animal Health Technician, collecting samples and inspecting animals for compliance with federal regulations. Abigail was also part of an emergency response team to eradicate the avian flu virus.
Throughout their career, Abigail has demonstrated strong leadership skills, the ability to manage cross-functional teams, and a track record of cost savings and process improvements.
Abigail Romaine completed their Bachelor of Science (B.S.) in Animal Sciences at Rutgers University from 1999 to 2003. Abigail also obtained additional certifications, including the Certified Advanced Procurement Professional from the Procurement Academy in 2017 and the LAT certification from AALAS.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.